Anti-CEA-CAR T / Southwest Hospital - LARVOL DELTA

HITM-SIR: Phase Ib trial of CAR-T hepatic artery infusions and selective internal radiation therapy for liver metastases (AACR 2017) - "In the previous Hepatic Immunotherapy for Metastases (HITM) phase I study we demonstrated the safety and biologic activity of anti-CEA CAR-T cell hepatic artery infusions (HAI). Following this phase Ib trial, the recommended phase 2 dose for anti-CEA CAR-T HITM infusions is 1010 cells with or without SIRT. The favorable safety profile and evidence of biologic activity indicate that CAR-T HITM infusions should be further studied in a phase 2 trial."

CAR T-Cell Therapy • Clinical • P1 data • P2/3 data • P3 data • Biosimilar • Immunology • Oncology

HITM-SURE: Phase Ib CAR-T hepatic artery infusion trial for stage IV adenocarcinoma using PressureEnabled Drug Delivery technology (SITC 2018) - P1; "Trial Registration NCT02850536; Background Prior Hepatic Immunotherapy for Metastases (HITM) phase I/Ib studies demonstrated the safety and biologic activity of anti-CEA CAR-T cell hepatic artery infusions (HAI) for CEA+ liver metastases (LM). The median OS compares favorably with prior HITM studies and presently approved second/third line regimens. Final results will inform design and device choice for larger studies."

IO biomarker • P1 data • PD(L)-1 Biomarker • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Pancreatic Cancer • Solid Tumor